Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions.

"We pride ourselves on being at the forefront of today's aesthetics market by developing and delivering best-in-class medical technologies and products that are exceptionally safe and effective," says Jeff Bedard, President and CEO of Crown. "This strategic acquisition furthers Crown's mission to drive innovation and provide superior products and customer service to aesthetics providers around the world. Eclipse's excellent products will broaden our product line and customer base, domestically and internationally."

"We are thrilled to have completed this transaction with Crown," adds Paul O'Brien, CEO of Eclipse. "The combination of Eclipse's innovative product offerings with Crown's leadership position in the aesthetics market will undoubtedly expand the reach and optimize the range of services health care professionals can provide to their patients."

As an innovative company focused on skin science, Crown will integrate the Eclipse products into the Aesthetics business unit of Crown to complement its SkinPen® Precision and other brands. Eclipse customers can expect to continue receiving superior customer service, medical education, and access to Crown's expanded range of highly effective aesthetic products.